See also: iX Biopharma secures licence to manufacture cannabis in Australia
SINGAPORE (Apr 29): iX Biopharma has entered into a supply agreement with Cannatrek, a medical cannabis enterprise, to supply Xativa, the world’s first freeze-dried sublingual medicinal cannabis wafer in Australia.
The agreement, which was signed by iX Biopharma’s wholly-owned subsidiary, iX Syrinx, marks the group’s official entry into the high-growth Australian cannabis market, which is expected to grow from US$0.04 billion (or S$0.05 billion) in 2020 to US$1.23 billion (S$1.74 billion) by 2024.
